Therapy‐related myeloid neoplasms (t‐MN) are a complication of cytotoxic treatment for
primary tumors and autoimmune diseases. We report data on 277 t‐MN patients, recruited …

Purpose: Epigenetic changes play a role and cooperate with genetic alterations in the
pathogenesis of myelodysplastic syndromes (MDS). We conducted a phase II multicenter study on …

Background Although hypomethylating agents are currently used to treat patients with
cancer, whether they can also reactivate and up-regulate oncogenes is not well elucidated. …

Background: Polymorphisms in genes involved in detoxification and DNA-repair pathways
may modify the individual's risk for genomic damage, and, as a consequence, the risk of …

Therapy-related myeloid neoplasms (t-MNs) include diseases onsetting in patients treated
with chemo- and/or radiotherapy for a primary cancer, or an autoimmune disorder. Genomic …

BRCA1 plays a pivotal role in the repair of DNA damage, especially following chemotherapy
and ionising radiation. We were interested in the regulation of BRCA1 expression in acute …

The azanucleotides azacitidine and decitabine have been shown to induce hematologic
response and prolong survival in higher-risk myelodysplastic syndromes. They are inhibitors of …

Bone marrow mesenchymal stem cells (BM-MSCs) exhibit multiple abnormalities in myelodysplastic
syndromes (MDS), including impaired proliferative and clonogenic capacity, altered …

Epigenetic changes play a role in the pathogenesis of myeloid malignancies, and
hypomethylating agents have shown efficacy in these diseases. We studied the apoptotic effect, …

Somatic mutations have been shown to play a significant prognostic role in myelodysplastic
syndromes (MDS). Actually, detection of a TP53, EZH2, RUNX1, ASXL1, or ETV6 mutation …